Schmidt L G, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönhöfer P S
Br J Psychiatry. 1986 Jan;148:38-43. doi: 10.1192/bjp.148.1.38.
We reviewed data on adverse drug reactions (ADRs) to first- and second-generation antidepressants, recorded by two different drug surveillance systems. The rate of ADRs that led to discontinuation of the drug in the individual case, assessed within a multi-centered hospital-based drug monitoring system (AMUP), was significantly higher in case of exposure to tricyclics (7.4%) than with the second-generation drugs (3.1%). On the basis of voluntary reports to the Medicines Commission of the German Medical Profession (AMK), profiles of ADRs to the drugs under survey were constructed and compared with data compiled by the WHO. The types of ADRs varied more between second-generation drugs than between tricyclics. Special attention was paid to rare but serious ADRs (e.g. seizures during treatment with maprotiline, and blood dyscrasias attributed to mianserin).
我们回顾了由两个不同药物监测系统记录的关于第一代和第二代抗抑郁药的药物不良反应（ADR）数据。在一个多中心医院药物监测系统（AMUP）中评估的导致个体病例停药的ADR发生率，在使用三环类药物的情况下（7.4%）显著高于第二代药物（3.1%）。根据向德国医学专业药品委员会（AMK）的自愿报告，构建了所调查药物的ADR概况，并与世界卫生组织汇编的数据进行了比较。第二代药物之间的ADR类型差异比三环类药物之间更大。特别关注了罕见但严重的ADR（例如，使用马普替林治疗期间的癫痫发作，以及归因于米安色林的血液系统疾病）。
